Finoriq research workspace
Benitec Biopharma Inc. (BNTC) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Benitec Biopharma Inc. (BNTC).
Company Snapshot
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
- Company
- Benitec Biopharma Inc. (BNTC)
- Ticker
- BNTC
- Market Cap
- $410.9M
- Latest Price
- $11.96
- Industry
- Biotech & Pharma
Benitec Biopharma Inc. (BNTC) Recent Insider Transactions
Recent market insider transaction records indexed for Benitec Biopharma Inc. (BNTC).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLCCommon stock, par value $0.0001 per share | P | Acquired | $884,352 | 2025-12-29 |
| SUVRETTA CAPITAL MANAGEMENT, LLCCommon stock, par value $0.0001 per share | P | Acquired | $155,729 | 2025-12-29 |
| Cowen AaronCommon stock, par value $0.0001 per share | P | Acquired | $884,352 | 2025-12-29 |
| Cowen AaronCommon stock, par value $0.0001 per share | P | Acquired | $155,729 | 2025-12-29 |
| Averill Master Fund, Ltd.Common stock, par value $0.0001 per share | P | Acquired | $884,352 | 2025-12-29 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.